The First 90 Days for a Pharma Programmatic Associate Director
A 30-60-90 day operating plan for pharma programmatic leaders covering governance, portfolio diagnosis, measurement, talent, partners, and investment.
The short answer
In the first 90 days, clarify decision rights, learn the business and evidence base, diagnose portfolio risk, strengthen one repeatable operating system, and turn the findings into a prioritized investment and talent plan. Avoid changing platforms or partners before understanding the root problem.
Days 1 to 30: establish ground truth
- Confirm role expectations, portfolio, and decision authority.
- Map brand, agency, activation, analytics, regulatory, privacy, procurement, and partner stakeholders.
- Read current plans, contracts, measurement methods, approval processes, incident logs, and QBR actions.
- Reconcile budget, audience, supply, frequency, and outcome definitions.
- Observe team workflows and identify overloaded single points of failure.
Deliverable: a fact base listing definitions, commitments, risks, and unanswered questions, not a premature transformation deck.
Days 31 to 60: prioritize systems
| System | Diagnostic |
|---|---|
| Investment | Does every major line have a job and stop rule? |
| Audience | Are provenance, overlap, eligibility, and match visible? |
| Supply | Can the team identify what actually delivered? |
| Measurement | Are attribution, incrementality, and projections separated? |
| Operations | Are decision rights, QA, and escalation explicit? |
| Talent | Does work match role level and development goals? |
Choose one or two improvements with portfolio leverage, such as a measurement brief, partner scorecard, or decision log. Stabilize urgent risks first.
Days 61 to 90: make and socialize choices
Present a portfolio view of keep, repair, test, consolidate, and stop recommendations. Attach owner, timing, expected benefit, cost, dependency, and evidence threshold. Establish a recurring operating cadence for investment, quality, measurement, and team development.
Lead the agency and partner ecosystem
Set expectations for recommendation quality, escalation, staffing, and transparency. Ask partners to expose assumptions and limitations. Do not use a new role to reopen every vendor decision; concentrate on choices where new evidence could change value.
Demonstrate director-level judgment
Strong leadership makes tradeoffs legible. It separates urgent from important, delegates execution with controls, protects specialist review, and translates analysis into a financial or operational choice. It also says “inconclusive” when evidence does not support a stronger claim.
Practical takeaway
The first 90 days should leave the organization with clearer decisions and a stronger operating system. The next step is a one-page charter containing five outcomes, five relationships, five risks, and the evidence that defines progress.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.